| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 4 1646-1653, Copyright © 1996 by American Association of Immunologists
ARTICLES |
HM Lorenz, C Antoni, T Valerius, R Repp, M Grunke, N Schwerdtner, H Nusslein, J Woody, JR Kalden and B Manger
Department of Internal Medicine III, University of Erlangen-Nuremberg, Germany.
Due to the unknown etiology of RA, specific treatment is not available. Recently, in a double-blinded, placebo-controlled clinical trial, in vivo blockade of TNF-alpha by a single infusion of a chimeric TNF-alpha- blocking mAb, cA2, has proven to be highly effective in the treatment of RA. In parallel to this trial, we tested the consequences of cA2 infusion in ex vivo and in vitro experiments. In this paper, we describe an increase in CD4+ and CD8+ T lymphocyte counts on day 1 and a marked decrease in monocyte counts preferentially on day 7 after cA2 treatment, without major changes in B lymphocyte or NK cell counts. In addition, we found an increased responsiveness of PBMC to CD28 mAb/PMA, but not to CD3 mAb, superantigen staphylococcus enterotoxin B, or PHA on day 1 after infusion. The increase in DNA synthesis of PBMC was paralleled by increased IL-2 mRNA and IL-4 mRNA expression and IL-2 protein secretion in culture supernatants after in vitro stimulation of PBMC with CD28 mAb/PMA. In PBMC, we did not find any significant changes in mRNA or protein expression of CD28 Ag or CD28 ligands, B7-1 and B7-2. Serum concentrations of IL-1 beta, IL-6, and soluble CD14 were significantly diminished after in vivo TNF-alpha blockade. We did not see relevant changes in granulocyte function in vitro after cA2 infusion. Finally, we observed a statistically significant decrease in slCAM-1 molecules in the serum of patients treated with verum compared with that in the serum of subjects given placebo. This change in slCAM- 1 concentration was evident on days 1 and 7 after the infusion of 10 mg/kg cA2, whereas it occurred only on day 7 in the serum of patients treated with the low dose (1 mg/kg) of cA2.
This article has been cited by other articles:
|
|
 |
|
  J Clark, P Vagenas, M Panesar, and A P Cope What does tumour necrosis factor excess do to the immune system long term? Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv70 - iv76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Heinzelmann and H. Bosshart Heparin Binds to Lipopolysaccharide (LPS)-Binding Protein, Facilitates the Transfer of LPS to CD14, and Enhances LPS-Induced Activation of Peripheral Blood Monocytes J. Immunol., February 15, 2005; 174(4): 2280 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Nissinen, M Leirisalo-Repo, R Peltomaa, T Palosuo, and O Vaarala Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis Ann Rheum Dis, June 1, 2004; 63(6): 681 - 687. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. P. Cope Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis Rheumatology, June 1, 2003; 42(6): 716 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Schuerwegh, J. F. Van Offel, W. J. Stevens, C. H. Bridts, and L. S. De Clerck Influence of therapy with chimeric monoclonal tumour necrosis factor-{alpha} antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients Rheumatology, April 1, 2003; 42(4): 541 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A A den Broeder, L A B Joosten, T Saxne, D Heinegard, H Fenner, A M M Miltenburg, W L H Frasa, L J van Tits, W A Buurman, P L C M van Riel, et al. Long term anti-tumour necrosis factor {alpha} monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation Ann Rheum Dis, April 1, 2002; 61(4): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A F Wahl and P M Wallace Oncostatin M in the anti-inflammatory response Ann Rheum Dis, November 1, 2001; 60(90003): iii75 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Barrera, L A B Joosten, A A den Broeder, L B A van de Putte, P L C M van Riel, and W B van den Berg Effects of treatment with a fully human anti-tumour necrosis factor {alpha} monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF{alpha} in patients with rheumatoid arthritis Ann Rheum Dis, July 1, 2001; 60(7): 660 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nishimoto, A. Ito, M. Ono, H. Tagoh, T. Matsumoto, T. Tomita, T. Ochi, and K. Yoshizaki IL-6 inhibits the proliferation of fibroblastic synovial cells from rheumatoid arthritis patients in the presence of soluble IL-6 receptor Int. Immunol., February 1, 2000; 12(2): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Charles, M. J. Elliott, D. Davis, A. Potter, J. R. Kalden, C. Antoni, F. C. Breedveld, J. S. Smolen, G. Eberl, K. deWoody, et al. Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-TNF-{alpha} Therapy in Rheumatoid Arthritis J. Immunol., August 1, 1999; 163(3): 1521 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Wallace, J. F. MacMaster, K. A. Rouleau, T. J. Brown, J. K. Loy, K. L. Donaldson, and A. F. Wahl Regulation of Inflammatory Responses by Oncostatin M J. Immunol., May 1, 1999; 162(9): 5547 - 5555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cauwels, K. Frei, S. Sansano, C. Fearns, R. Ulevitch, W. Zimmerli, and R. Landmann The Origin and Function of Soluble CD14 in Experimental Bacterial Meningitis J. Immunol., April 15, 1999; 162(8): 4762 - 4772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jorgensen, F. Apparailly, and J. Sany Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt? Ann Rheum Dis, March 1, 1999; 58(3): 136 - 141. [Full Text]
|
|
|
|
 |
|
 E. Lien, P. Aukrust, A. Sundan, F. Muller, S. S. Froland, and T. Espevik Elevated Levels of Serum-Soluble CD14 in Human Immunodeficiency Virus Type 1 (HIV-1) Infection: Correlation to Disease Progression and Clinical Events Blood, September 15, 1998; 92(6): 2084 - 2092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Carballo, W. S. Lai, and P. J. Blackshear Feedback Inhibition of Macrophage Tumor Necrosis Factor-  Production by TristetraprolinScience, August 14, 1998; 281(5379): 1001 - 1005. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. J. Hawkey, W. A. Stack, J. Bauditz, H. Lochs, S. Schreiber, S. R. Targan, and T. F. Schaible Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor {alpha} for Crohn's Disease N. Engl. J. Med., January 29, 1998; 338(5): 333 - 334. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
